Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
ACL Stock Chart & Stats
AU$2.04
AU$0.08(2.29%)
At close: 4:00 PM EST
AU$2.04
AU$0.08(2.29%)
Day’s Range― - ―
52-Week RangeAU$1.92 - AU$3.24
Previous CloseN/A
Volume421.17K
Average Volume (3M)867.30K
Market Cap
AU$383.87M
Enterprise ValueAU$815.46M
Total Cash (Recent Filing)AU$23.14M
Total Debt (Recent Filing)AU$453.61M
Price to Earnings (P/E)23.9
Beta0.98
Next Earnings
Aug 26, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend Yield4.6%
Share Statistics
EPS (TTM)0.07
Shares Outstanding189,100,140
10 Day Avg. Volume799,589
30 Day Avg. Volume867,296
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.09
Price to Sales (P/S)0.71
P/FCF Ratio3.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.33Price Target Upside14.22% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.17
Revenue Forecast (FY)AU$736.49M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent FCF growth and high cash conversion (OCF/NI 0.84, FCF/NI 0.95) indicate the business reliably turns accounting earnings into cash. Durable cash generation underpins dividends, capex funding, debt servicing and strategic flexibility over the next several quarters.
Improving Gross MarginA materially higher gross margin (36.54%) reflects structural gains in operational efficiency or pricing mix. Sustained margin expansion supports profitability resilience against volume volatility and strengthens long-term earnings power without relying solely on revenue growth.
High Return On EquityROE near 19% signals the company generates solid returns on shareholder capital, supporting sustainable dividend capacity and shareholder value creation. If maintained, this level of ROE helps justify reinvestment and supports long-term growth even with modest revenue increases.
Bears Say
High Financial LeverageA debt-to-equity ratio of 1.69 creates structural vulnerability: higher interest burden and less financial flexibility. In a lower-growth or reimbursement-pressured environment, leverage magnifies downside risk and can constrain investments or require cash for servicing rather than growth.
Low Net Profit MarginA sub-5% net margin means most revenue is absorbed by operating costs, interest and taxes. This persistent low profitability reduces buffer against cost inflation or reimbursement cuts, limiting retained earnings for reinvestment and making earnings volatile to small revenue shifts.
Modest Revenue GrowthNear-flat top-line growth indicates limited organic expansion in core pathology volumes or pricing. Over the medium term, stagnant revenue constrains scale benefits, raising reliance on margin improvements or M&A to drive meaningful earnings growth and justify ongoing capex.
Australian Clinical Labs Ltd News
ACL FAQ
What was Australian Clinical Labs Ltd’s price range in the past 12 months?
Australian Clinical Labs Ltd lowest share price was AU$1.92 and its highest was AU$3.24 in the past 12 months.
What is Australian Clinical Labs Ltd’s market cap?
Australian Clinical Labs Ltd’s market cap is AU$383.87M.
When is Australian Clinical Labs Ltd’s upcoming earnings report date?
Australian Clinical Labs Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 144 days.
How were Australian Clinical Labs Ltd’s earnings last quarter?
Australian Clinical Labs Ltd released its earnings results on Feb 15, 2026. The company reported AU$0.067 earnings per share for the quarter, missing the consensus estimate of AU$0.073 by -AU$0.006.
Is Australian Clinical Labs Ltd overvalued?
According to Wall Street analysts Australian Clinical Labs Ltd’s price is currently Undervalued.
Does Australian Clinical Labs Ltd pay dividends?
Australian Clinical Labs Ltd pays a Semiannually dividend of AU$0.09 which represents an annual dividend yield of 4.6%. See more information on Australian Clinical Labs Ltd dividends here
What is Australian Clinical Labs Ltd’s EPS estimate?
Australian Clinical Labs Ltd’s EPS estimate is 0.1.
How many shares outstanding does Australian Clinical Labs Ltd have?
Australian Clinical Labs Ltd has 189,100,140 shares outstanding.
What happened to Australian Clinical Labs Ltd’s price movement after its last earnings report?
Australian Clinical Labs Ltd reported an EPS of AU$0.067 in its last earnings report, missing expectations of AU$0.073. Following the earnings report the stock price went up 6.768%.
Which hedge fund is a major shareholder of Australian Clinical Labs Ltd?
Currently, no hedge funds are holding shares in AU:ACL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Australian Clinical Labs Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$2.33 (14.22% Upside)
AU$2.33 (14.22% Upside)
Insider Transactions
Bought Shares
Worth AU$50.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.73%
12-Months-Change
Fundamentals
Return on Equity
16.35%
Trailing 12-Months
Asset Growth
-3.86%
Trailing 12-Months
Company Description
Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
ACL Stock 12 Month Forecast
Average Price Target
AU$2.33
▲(14.22% Upside)
Technical Analysis
Options Prices
Currently, No data available
---